Delving into the Latest Updates on CoTend-s3BXBB with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

SARS2-17032

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Tendel Therapies, Inc.

Active Organization

Tendel Therapies, Inc.

University of California, Los Angeles

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called "s3", which was designed to improve the body's response to the vaccine. CoTend-BXBB is the same vaccine without s3.
The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does "s3" lead to bigger, broader, and longer-lasting responses to the vaccine?
5 different doses of the vaccines will be studied. Participants will receive a single dose of either CoTend-s3BXBB, CoTend-BXBB, or placebo. Participants will be monitored for side effects. Saliva, nasal, and blood samples will be collected and immune responses to the vaccine will be measured.

Start Date15 May 2025

Sponsor / Collaborator

University of California, Los Angeles

[+3]

100 Clinical Results associated with CoTend-s3BXBB

Login to view more data

100 Translational Medicine associated with CoTend-s3BXBB

Login to view more data

100 Patents (Medical) associated with CoTend-s3BXBB

Login to view more data

100 Deals associated with CoTend-s3BXBB

Login to view more data